Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Cash and Equivalents of $1.31 billion for fiscal year 2025.
BIOMARIN PHARMACEUTICAL INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.31B | +39.1% |
| 2024 | $942.84M | +24.9% |
| 2023 | $755.13M | +4.2% |
| 2022 | $724.53M | +23.4% |
| 2021 | $587.28M | -9.5% |
| 2020 | $649.16M | +48.4% |
| 2019 | $437.45M | -11.4% |
| 2018 | $493.98M | -17.4% |
| 2017 | $598.03M | +46.5% |
| 2016 | $408.33M | +2.8% |
| 2015 | $397.04M | -54.6% |
| 2014 | $875.49M | +53.9% |
| 2013 | $568.78M | +215.1% |
| 2012 | $180.53M | +290.1% |
| 2011 | $46.27M | -47.5% |
| 2010 | $88.08M | -47.3% |
| 2009 | $167.17M | -25.0% |
| 2008 | $222.90M | -2.4% |
| 2007 | $228.34M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.25B | +85.1% | +3.0% |
| June 30, 2025 | $1.21B | +24.9% | +15.7% |
| March 31, 2025 | $1.05B | +40.4% | +11.2% |
| December 31, 2024 | $942.84M | +24.9% | +39.6% |
| September 30, 2024 | $675.45M | -14.0% | -30.5% |
| June 30, 2024 | $972.15M | +40.0% | +30.1% |
| March 31, 2024 | $747.00M | +28.8% | -1.1% |
| December 31, 2023 | $755.13M | +4.2% | -3.9% |
- BIOMARIN PHARMACEUTICAL INC showed an increase of +39.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, BIOMARIN PHARMACEUTICAL INC’s cash and equivalents has grown by 474.4% (from $228.34 million to $1.31 billion).
- The most recent figure is from BIOMARIN PHARMACEUTICAL INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: